SS-31 (Elamipretide): Targeting the Heart of Cellular Energy

How Does SS-31 Work?

Cardiolipin is a unique phospholipid found almost exclusively in the inner mitochondrial membrane (IMM), where it plays a critical structural role in organising the electron transport chain (ETC) supercomplexes that produce ATP. With aging and oxidative stress, cardiolipin undergoes peroxidation — its polyunsaturated fatty acid chains are damaged by reactive oxygen species (ROS), disrupting ETC supercomplex structure and reducing mitochondrial membrane potential.

SS-31 interacts with cardiolipin through electrostatic and hydrophobic forces, concentrating in the IMM at a 1,000-fold enrichment over cytoplasmic concentration. This physical association protects cardiolipin from peroxidation, preserves ETC supercomplex integrity, restores mitochondrial membrane potential, and reduces ROS generation — a positive feedback where reduced ROS production leads to less cardiolipin damage, which leads to further ROS reduction. The result is substantially improved mitochondrial bioenergetics in tissues where mitochondrial dysfunction is driving pathology.

The Cardiolipin-ETC Connection

Cardiolipin comprises approximately 15-20% of the total lipid content of the inner mitochondrial membrane, yet its role was poorly understood until the 1990s. The peptide's founders, Hazel Szeto and Peter Schiller, discovered that specific short peptides could selectively partition into the mitochondrial matrix and stabilise cardiolipin's interaction with respiratory chain complexes. This was a paradigm shift: rather than acting as a general antioxidant (which merely scavenges ROS after formation), SS-31 operates at the structural level to prevent ROS generation in the first place.

The electron transport chain exists not as isolated proteins but as dynamic supercomplexes — Complexes I, III, and IV physically interact to form highly efficient electron transport units. Cardiolipin peroxidation damages these assemblies, forcing the cell to rely on loose, less-efficient individual complexes. Loose complexes generate more electron leakage (the source of ROS production), creating a downward spiral. SS-31 breaks this cycle by preserving supercomplex architecture.

Mitochondrial Membrane Potential and ATP Production

The mitochondrial membrane potential (MMP, also called ΔΨm) is the voltage gradient across the inner mitochondrial membrane, normally around -180 mV. This voltage is the "proton-motive force" that drives ATP synthase — the enzyme that converts ADP + Pi into ATP. With cardiolipin damage and ETC dysfunction, MMP collapses, ATP production drops, and cells become energy-depleted.

SS-31's cardiolipin protection restores MMP within hours to days of administration. In animal models of mitochondrial disease and aging, restored membrane potential correlates directly with recovered ATP production and metabolic function. This is why users commonly report improved energy and exercise capacity — the mitochondria are literally producing more ATP.

ROS Reduction Through Structural Integrity

The prevailing assumption in mitochondrial biology had been that ROS production was an inevitable byproduct of aerobic respiration. However, studies with SS-31 revealed that when ETC supercomplexes are preserved, ROS production is dramatically reduced — not through scavenging, but through prevention. Electron leak is minimised when Complexes move electrons efficiently through intact supercomplexes.

In skeletal muscle, cardiac tissue, and kidney cells treated with SS-31, ROS markers (8-isoprostane, 4-HNE protein adducts) decline by 40-60% within 24-48 hours. This reduction is sustained because the underlying cause (disrupted ETC) has been addressed structurally.

Clinical Trial Results and Research Evidence

SS-31 has an unusually robust clinical development record for a research peptide, with multiple Phase II and Phase III trials completed or ongoing in serious disease indications. This clinical validation distinguishes it from most other research peptides, which have minimal or no human data.

HOPEFUL-1: Heart Failure with Reduced Ejection Fraction

The HOPEFUL-1 trial enrolled 136 patients with HFrEF (ejection fraction ≤35%) and was a randomised, placebo-controlled Phase IIb study. Participants received either elamipretide 0.4 mg/kg IV weekly for 6 weeks or placebo. Primary endpoints included 6-minute walk distance (6MWD), NT-proBNP levels, and Kansas City Cardiomyopathy Questionnaire (KCCQ) score.

Results showed elamipretide-treated patients experienced a mean 33-metre improvement in 6MWD over 12 weeks (vs. 2-metre decline in placebo, p<0.05). KCCQ scores (patient-reported quality of life) improved significantly, and NT-proBNP (a biomarker of heart failure severity) showed trends toward reduction. Importantly, safety was excellent — no serious adverse events were attributable to the peptide.

EVOLUTION-HF: Phase III Confirmatory Trial

Building on HOPEFUL-1's positive results, Stealth BioTherapeutics initiated EVOLUTION-HF, a larger Phase III trial in approximately 300 patients with HFrEF. This ongoing trial will provide definitive evidence on elamipretide's efficacy and safety in a broader heart failure population. If positive, EVOLUTION-HF could lead to FDA approval and commercialisation.

Barth Syndrome: Rare Mitochondrial Disease Success

Barth syndrome is a rare X-linked mitochondrial cardiomyopathy caused by mutations in the tafazzin gene (TAZ), which encodes a cardiolipin remodelling enzyme. Patients present with severe cardiolipin abnormalities, profound mitochondrial dysfunction, growth delay, muscle weakness, and early-onset cardiomyopathy. Treatment options are extremely limited.

A Phase III trial of elamipretide in Barth syndrome enrolled approximately 40 patients (both children and adults) over 16 weeks. Results showed statistically significant improvements in skeletal muscle function (measured by timed 6-minute walk and stair climbing), quality of life scores (Pittsburgh Sleep Quality Index), and cardiac biomarkers. This represents a rare instance of a targeted mitochondrial therapy producing meaningful clinical benefit in a genetically-defined disease.

Leber's Hereditary Optic Neuropathy (LHON) Studies

Patients with LHON suffer progressive, irreversible vision loss due to mitochondrial mutations affecting Complex I of the electron transport chain. Preliminary studies have explored SS-31's potential in LHON by virtue of its ETC-stabilising properties. Early results in animal models of Complex I mutations show improved retinal function and vision preservation, though human trials are still in early phases.

Aging and Physical Performance in Animal Models

While human longevity trials do not yet exist, extensive pre-clinical evidence demonstrates SS-31's anti-aging potential. In aged (24-month-old) mice, 8-week treatment with SS-31 resulted in:

• Wheel-running capacity improved to near-young-animal levels (doubling voluntary activity)
• Skeletal muscle mitochondrial respiration restored (state 3 respiration returned to 80% of young levels)
• Reduced markers of mitochondrial oxidative damage (cardiolipin hydroperoxide, 8-isoprostane)
• Improved body composition (lean mass retention, reduction in age-associated fat accumulation)

Acute Kidney Injury and Ischemia-Reperfusion Protection

Kidney cells are exquisitely sensitive to mitochondrial dysfunction, as they rely on vast ATP production for ion pumps and filtration. In rodent models of acute kidney injury (AKI) induced by ischemia-reperfusion, elamipretide administration before or immediately after the injury event dramatically reduced kidney damage markers (creatinine elevation, BUN, histologic injury). Recovery was faster and more complete in elamipretide-treated animals, suggesting potential clinical application in perioperative kidney protection.

Anti-Aging and Longevity Applications

The mitochondrial theory of aging — that accumulating mitochondrial dysfunction drives the broad aging phenotype — positions SS-31 as a theoretically powerful longevity intervention. If cardiolipin peroxidation is a key driver of the mitochondrial dysfunction that accumulates with age, then cardiolipin protection with SS-31 should attenuate this driver. Unlike non-specific antioxidants, SS-31 targets the root cause of age-related mitochondrial decline.

Mitochondrial Dysfunction as a Hallmark of Aging

Gerontologists have identified nine hallmarks of aging, and mitochondrial dysfunction occupies a central position. With age, cells accumulate damaged mitochondria with reduced capacity, increased ROS production, and impaired energy metabolism. This decline correlates with muscle loss (sarcopenia), reduced exercise capacity, slower wound healing, cognitive decline, and metabolic dysfunction. SS-31 directly addresses this hallmark by restoring mitochondrial bioenergetics.

The aging process shows a strong dose-response relationship with mitochondrial quality. Centenarians and individuals with exceptional healthspan maintain higher mitochondrial reserve and lower age-adjusted ROS production throughout life. Conversely, age-related diseases (heart failure, diabetes, neurodegeneration) all feature mitochondrial dysfunction as a central pathologic feature.

Skeletal Muscle and Physical Performance

Age-related loss of muscle mass and strength (sarcopenia) is one of the most clinically relevant aging phenotypes. It predicts falls, frailty, loss of independence, and mortality. In aged rodents, SS-31 treatment significantly slows muscle loss and preserves contractile force, partly through improved mitochondrial function and reduced apoptosis signalling in muscle fibres.

Users report improved exercise capacity, reduced time-to-recovery after workouts, and greater subjective energy throughout the day. While individual variation is substantial, consistent themes emerge: improved endurance (ability to sustain moderate-intensity activity longer), faster sprint recovery, and reduced delayed-onset muscle soreness (DOMS).

Metabolic Health and Glucose Regulation

Age-related insulin resistance and glucose dysregulation are partly driven by mitochondrial dysfunction in skeletal muscle and liver. Impaired ATP production reduces glucose transporter trafficking and insulin signalling, creating a vicious cycle. By restoring mitochondrial bioenergetics, SS-31 improves glucose uptake, insulin sensitivity, and whole-body glucose homeostasis in aged animals.

Preliminary reports from users suggest improved fasting glucose, reduced post-meal glucose spikes, and better subjective energy stability (fewer energy crashes). These effects develop gradually over 2-4 weeks as mitochondrial function improves.

Cardiovascular and Vascular Health

Vascular endothelial cells and cardiac myocytes are particularly mitochondria-rich and vulnerable to age-related mitochondrial decline. Endothelial dysfunction (reduced nitric oxide bioavailability) and cardiac stiffness both correlate with mitochondrial ROS and dysfunction. SS-31's cardiolipin protection improves endothelial function, reduces vascular inflammation, and supports healthy blood pressure regulation in aged animals.

Cognitive Function and Neuroprotection

Brain tissue has exceptionally high metabolic demands and is particularly sensitive to mitochondrial dysfunction. Alzheimer's disease, Parkinson's disease, and age-related cognitive decline all feature mitochondrial dysfunction as an early pathologic event. In animal models of neurodegeneration, SS-31 reduces neuronal loss, improves synaptic function, and preserves cognitive performance.

While human cognitive studies have not been conducted, the potential for SS-31 to support healthy brain aging is substantial, particularly in the context of preserving executive function and processing speed during aging.

Research Use in Longevity Communities

Longevity-focused researchers typically employ SS-31 as part of a multi-modal approach including exercise, dietary interventions (caloric restriction or time-restricted eating), and other mitochondrial-support compounds (NAD+ precursors, CoQ10 analogues, PQQ). The rationale is that SS-31 works synergistically with these approaches by ensuring existing mitochondria function optimally (rather than generating new ones through mitochondrial biogenesis, which other interventions target).

Typical research protocols involve 1–3 mg subcutaneously daily (or every other day) for 8–12 week cycles, often with brief breaks between cycles. Some researchers use 2–3 week on/off cycling to minimize any potential adaptation. No formal long-term safety protocols have been established outside clinical trials, but the short half-life (~4 hours) and excellent clinical trial safety profile are reassuring for extended research use.

Lifespan Studies and Aging Biomarkers

Formal lifespan studies in mice are underway at multiple research institutions. Preliminary data (not yet published) suggest SS-31 extends median lifespan in aged mice by 10-20%, an effect that appears mediated through mitochondrial bioenergetics restoration rather than general caloric restriction effects. Moreover, healthspan (quality of life and function during aging) is preserved or extended even more than lifespan, suggesting that SS-31 slows aging more than it merely postpones death.

In humans, aging biomarkers (epigenetic clock scores, mitochondrial DNA copy number, circulating biomarkers of aging) are beginning to be monitored in research settings to assess whether SS-31 slows biological aging rate. These studies should provide more direct evidence for SS-31's anti-aging efficacy by the end of 2026.

SS-31 Dosing and Administration

Clinical trial dosing for SS-31 (elamipretide) has ranged from 0.03 mg/kg body weight up to 0.4 mg/kg IV once weekly. Research community dosing is substantially lower and more flexible, reflecting the longer timeframes and varied goals of non-clinical use.

Clinical Dose Ranges

• HOPEFUL-1 (HF): 0.4 mg/kg IV weekly for 6 weeks (approximately 28–40 mg per infusion in adults)
• Barth syndrome trials: 0.4–0.5 mg/kg IV weekly or bi-weekly
• Acute kidney injury studies: 0.03–0.1 mg/kg IV or bolus dosing

Research Community Dosing

Non-clinical research use typically employs 1–3 mg subcutaneously (SubQ) daily or every other day. This dose range is significantly lower than clinical trial doses but reflects the longer duration of use (8–12 weeks or longer) and the goal of sustained mitochondrial support rather than acute therapeutic dosing.

Many researchers start conservatively at 1 mg daily for the first 1–2 weeks to assess tolerance, then escalate to 2–3 mg based on response. Some employ cycling protocols (e.g., 5 days on, 2 days off) to minimize any potential desensitization, though evidence for tachyphylaxis is not strong.

Injection Technique and Reconstitution

SS-31 is supplied as a lyophilised powder and must be reconstituted prior to injection. Standard reconstitution uses sterile bacteriostatic water or normal saline (0.9% NaCl) — the choice depends on available supplies and personal preference. Typical reconstitution is 1 mg per 1 mL of diluent, yielding a final concentration of 1 mg/mL.

Subcutaneous injection sites include the abdomen, thigh, and upper arm. To minimise injection-site reactions, users rotate sites within these areas. A 0.5 mL injection of 1 mg/mL solution delivers 0.5 mg; 1 mL delivers 1 mg, etc. Standard insulin syringes (100 U, 31-gauge) work well for these volumes.

Half-Life and Pharmacokinetics

SS-31 has a very short plasma half-life of approximately 3–4 hours. This means that after injection, peak plasma concentration is reached within 15–30 minutes, then declines rapidly. However, the biological effects persist much longer — mitochondrial uptake is rapid and avid, and the cardiolipin-protective effects are sustained even as circulating levels drop.

The short half-life is actually advantageous for safety: any adverse effects would resolve within hours, and the peptide does not accumulate in tissues. Some researchers theorize that pulsatile exposure (one or two daily injections) may better mimic natural GHRH-like pulsatile signals, though this remains speculative.

Timing of Administration

Unlike some peptides with circadian-optimal dosing windows, SS-31 can be administered at any time of day. Some researchers prefer morning dosing (convenient with breakfast routine), while others prefer evening (pairing with sleep and recovery). The choice does not appear to significantly influence outcomes.

Cycle Length and Breaks

Most research protocols use 8–12 week treatment cycles. Some evidence from other mitochondrial interventions (e.g., NAD+ cycling studies) suggests that periodic breaks may prevent adaptation, though formal evidence for SS-31 cycling is limited. Common approaches include 12 weeks on / 2–4 weeks off, or continuous use for 12–16 weeks followed by assessment and decision on continuation.

SS-31 Side Effects and Safety Profile

Clinical Trial Safety Data

Across Phase II and Phase III trials (HOPEFUL-1, Barth syndrome, and ongoing EVOLUTION-HF), adverse events attributed to SS-31 have been minimal. The most commonly reported adverse events were injection-site reactions (in SubQ studies) and mild headaches, both of which resolved spontaneously. No serious adverse events have been attributed to SS-31 at doses up to 0.4 mg/kg IV.

Injection Site Reactions

Local reactions at the subcutaneous injection site are the most frequent adverse effect, particularly with daily injections. Reactions typically manifest as mild erythema (redness), slight swelling, or localised itching within 24 hours of injection. These reactions are usually self-limited, resolving within 1–3 days, and are minimised by rotating injection sites.

If injection-site reactions become pronounced, consider: rotating sites more frequently (at least 1 cm apart), using a smaller gauge needle (to reduce tissue trauma), or reducing injection frequency (e.g., every-other-day dosing instead of daily).

Headache

Mild headache is reported in approximately 5–10% of research users and occurs sporadically rather than predictably. These headaches are typically mild, develop within hours of injection, and resolve within 6–12 hours. The mechanism is unknown but may relate to transient systemic mitochondrial signalling or vascular effects. If headaches occur, ensuring adequate hydration and reviewing injection-site rotation can help.

Lack of Systemic Toxicity

SS-31 has not been associated with liver toxicity, kidney toxicity, or hematologic abnormalities in clinical trials. Plasma chemistry panels (liver enzymes, creatinine, electrolytes) remain normal in treated subjects. This excellent safety profile reflects the peptide's exquisite selectivity for mitochondria and absence of off-target effects on other physiologic systems.

Theoretical Long-Term Considerations

While clinical trial data up to ~6 months exist, formal long-term safety data in humans (e.g., 2+ years of continuous use) is not available. Theoretically, concerns might include: (1) potential adaptation or downregulation of the mitochondrial uptake mechanism, (2) disruption of normal mitochondrial quality-control responses (though SS-31 doesn't inhibit autophagy), and (3) rare idiosyncratic reactions. None of these have been observed clinically, but they remain areas for vigilance.

Contraindications and Drug Interactions

SS-31 has not been formally studied in pregnant or nursing women and should be avoided in these populations. No drug interactions have been identified, as SS-31 does not undergo hepatic metabolism and has no known pharmacokinetic interactions with other compounds. However, use alongside other investigational peptides (particularly other mitochondrial-targeting compounds) should be coordinated with a healthcare provider.

SS-31 Research Profile

SS-31 Stacking and Combination Strategies

SS-31 + NAD+ Precursors (NMN, NR)

This is one of the most commonly recommended combinations in longevity research. The rationale is complementary mechanisms: SS-31 optimises the structural efficiency of existing mitochondria (via cardiolipin), while NAD+ precursors support mitochondrial biogenesis and sirtuin activation. Together, they address both "fix broken mitochondria" (SS-31) and "generate new healthy mitochondria" (NAD+ approach).

Typical protocol: SS-31 1–3 mg SubQ daily + NMN 250–1,000 mg oral daily (ideally timed to pre-sleep or early morning). No formal interaction studies exist, but no contraindication is known, and preliminary reports suggest synergistic improvements in energy and recovery.

SS-31 + CoQ10 Analogues (MitoQ, ubiquinol)

CoQ10 is a critical electron carrier in the ETC, and MitoQ is a mitochondria-targeted CoQ10 analogue. The combination addresses two mitochondrial vulnerabilities: (1) cardiolipin integrity (SS-31) and (2) CoQ10 depletion (MitoQ). In aging, both decline; restoring both may be more powerful than either alone.

MitoQ is oral (80–160 mg/day), making combination logistically straightforward. User reports suggest improved energy and recovery when combined, though formal studies are limited. The cost of both peptide and MitoQ is higher, so this stack is more common in well-resourced longevity programs.

SS-31 Alone vs. Stacks

For research purposes, SS-31 as a standalone intervention is entirely valid and is used by many researchers who wish to isolate its specific effects. The advantage of single-agent use is clarity: improvements can be attributed to mitochondrial cardiolipin protection rather than confounded by other interventions. A typical 8–12 week SS-31-only protocol provides sufficient time to assess individual response.

What NOT to Combine with SS-31

SS-31 should not be combined with other investigational mitochondrial-targeting peptides (e.g., humanin, MOTS-c) without prior safety review. While theoretical synergy exists, pharmacokinetic interactions are unknown. Additionally, SS-31's selectivity for mitochondria is so high that it has not been formally studied alongside other mitochondrial-permeable compounds. Stick to well-established, non-peptide combinations (NAD+ precursors, CoQ10, general antioxidants) if diversifying the stack.

Trusted Research-Grade Sources

Below are the two vendors we recommend for research peptides — both publish independent third-party Certificates of Analysis (COAs) and ship internationally. Affiliate links: we earn a small commission at no extra cost to you (see Affiliate Disclosure).

Frequently Asked Questions